广东新宏泽包装股份有限公司 独立董事 2024 年度述职报告（黄贤畅） 各位董事： 本人作为广东新宏泽包装股份有限公司（以下简称"公司"）的第五届董事会 的独立董事，严格按照《公司法》、《上市公司独立董事管理办法》（以下简称"管 理办法"）、《公司章程》和《独立董事工作制度》等有关法律、法规和部门规章的 规定和要求，本着客观、公正、独立的原则，及时了解公司的生产经营及发展状况， 认真审议董事会各项议案，充分发挥独立董事及各专门委员会委员的作用，切实维 护了公司及全体股东尤其是中小股东的利益。现将 2024 年度履职情况汇报如下： 一、出席董事会及股东大会会议情况 在履职期间，本人能够投入足够的时间和精力，积极参加公司董事会及股东 大会会议，认真审阅相关资料，积极参与各项议题的讨论并提出合理建议，以严谨 的态度行使表决权，对公司董事会各项议案均投出赞成票，没有反对、弃权的情形， 也没有缺席董事会及股东大会的情形。报告期内，本人出席会议情况如下： 2、参与董事会专门委员会、独立董事专门会议具体工作情况 报告期内，公司董事会各专门委员会以及独立董事专门会议召开及本人参与 审议事项的具体情况如下： | 委员会 | 成 ...

广东新宏泽包装股份有限公司 信息披露暂缓与豁免业务管理制度 第一章 总则 第一条 广东新宏泽包装股份有限公司（以下简称"公司"）为规范信息披露 暂缓与豁免行为，确保公司及相关信息披露义务人（以下简称"信息披露义务 人"）依法依规履行信息披露义务，保护投资者的合法权益，根据《中华人民共 和国证券法》（以下简称《证券法》）、《上市公司信息披露管理办法》、《深 圳证券交易所股票上市规则》（以下简称《股票上市规则》）、《深圳证券交易 所上市公司自律监管指引第1号——主板上市公司规范运作》、《深圳证券交易 所上市公司自律监管指引第5号——信息披露事务管理》（以下简称《规范运作 指引》）等法律、法规、规范性文件及《广东新宏泽包装股份有限公司章程》 （以下简称《公司章程》）等内部规章制度的有关规定，结合公司实际情况，制 定本制度。 第二条 信息披露义务人按照《上市公司信息披露管理办法》、《股票上市规 则》及深圳证券交易所（以下简称"深交所"）其他相关业务规则的规定，办理 信息披露暂缓、豁免事务的，适用本制度。 第三条 应当披露的信息存在《股票上市规则》及深交所其他相关业务规则中 规定的可暂缓、豁免信息披露的情形的，可以无须 ...

广东新宏泽包装股份有限公司董事会 关于独立董事独立性自查情况的专项意见 根据中国证券监督管理委员会《上市公司独立董事管理办法》、《深圳证券交 易所股票上市规则》、《深圳证券交易所上市公司自律监管指引第 1 号——主板上 市公司规范运作》等要求，广东新宏泽包装股份有限公司（以下简称"公司"） 董事会就公司在任独立董事廖俊雄、黄贤畅、苏镜权的独立性情况进行评估并出 具如下专项意见： 经核查公司在任独立董事廖俊雄、黄贤畅、苏镜权的任职经历以及签署的相 关自查文件，上述人员未在公司担任除独立董事以外的任何职务，也未在公司主 要股东公司担任任何职务，与公司以及主要股东之间不存在利害关系或其他可能 妨碍其进行独立客观判断的关系，不存在影响独立董事独立性的情况，符合《上 市公司独立董事管理办法》、《深圳证券交易所上市公司自律监管指引第 1 号—— 主板上市公司规范运作》中对独立董事独立性的相关要求。 广东新宏泽包装股份有限公司董事会 2025 年 4 月 24 日 ...

一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.2800 | 0.0800 | 250 | 0.3700 | | 每股净资产（元） | 0 | 1.62 | -100 | 2.24 | | 每股公积金(元) | 0.15 | 0.15 | 0 | 0.18 | | 每股未分配利润(元) | 0.35 | 0.20 | 75 | 0.75 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 3.67 | 1.77 | 107.34 | 1.5 | | 净利润(亿元) | 0.62 | 0.19 | 226.32 | 0.84 | | 净资产收益率(%) | 17.40 | 4.85 | 258.76 | 21.22 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 15656.41万股，累计占流通股比： 67.95%，较上期变化： -529. ...

Financial Performance - The company's revenue for Q1 2025 reached ¥101,185,819.35, representing a 49.27% increase compared to ¥67,787,101.91 in the same period last year[5]. - Net profit attributable to shareholders was ¥16,007,339.18, up 51.17% from ¥10,588,916.36 year-over-year[5]. - Basic and diluted earnings per share rose to ¥0.07, reflecting a 40.00% increase from ¥0.05 in the same quarter last year[5]. - Total operating revenue for the current period reached ¥101,185,819.35, a significant increase of 48.9% compared to ¥67,787,101.91 in the previous period[16]. - Net profit for the current period was ¥16,007,339.18, representing a 51.5% increase from ¥10,588,916.36 in the previous period[17][18]. - Earnings per share increased to ¥0.07 from ¥0.05, reflecting improved profitability[18]. Cash Flow and Investments - The net cash flow from operating activities increased significantly by 167.54%, amounting to ¥40,699,642.49 compared to ¥15,212,300.59 in the previous year[5]. - Cash inflows from operating activities totaled ¥124,860,884.26, compared to ¥67,121,031.74 in the previous period, indicating a strong growth in cash generation[19]. - The net cash flow from investing activities was -$74,335,479.18, worsening from -$50,947,936.32, reflecting a decline of approximately 45.8%[20]. - Cash inflow from investment activities totaled $17,487,574.32, significantly lower than $140,455,962.18, a decrease of about 87.6%[20]. - Cash outflow from investment activities reached $91,823,053.50, down from $191,403,898.50, a reduction of approximately 52.0%[20]. Assets and Liabilities - Total assets at the end of the reporting period were ¥538,798,722.74, a 1.35% increase from ¥531,628,129.09 at the end of the previous year[5]. - The total current liabilities decreased from ¥39,247,060.25 to ¥30,963,654.62, a reduction of approximately 21.2%[14]. - The total liabilities decreased to ¥150,788,929.94 from ¥159,625,675.47, showing a reduction in financial obligations[15]. - Total equity attributable to shareholders increased to ¥388,009,792.80 from ¥372,002,453.62, indicating a growth in shareholder value[15]. Research and Development - The company reported a 60.47% increase in R&D expenses, totaling ¥5,000,427.98 compared to ¥3,116,025.11 in the previous year[8]. - Research and development expenses rose to ¥5,000,427.98, up from ¥3,116,025.11, highlighting the company's commitment to innovation[17]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 11,975[10]. - The largest shareholder, Yize Holdings Limited, holds 63.74% of the shares, totaling 146,846,880 shares[10]. - There are no known relationships or concerted actions among the top shareholders, except for some ownership connections[11]. - The company has no preferred shareholders or significant changes in shareholder financing activities[12]. Operating Costs and Income - Total operating costs amounted to ¥82,169,770.71, up 47.9% from ¥55,507,915.60 in the prior period, with operating costs specifically rising from ¥45,346,543.87 to ¥67,522,592.43[16][17]. - The company experienced a significant decrease in investment income, down 93.77% to ¥26,607.40, due to reduced returns from wealth management products[9]. - The company reported a significant increase in other income, which rose to ¥123,243.69 from ¥290,621.33, indicating fluctuations in non-operating income sources[17]. Cash and Cash Equivalents - The company's cash and cash equivalents decreased from ¥174,197,137.80 to ¥132,182,739.23, a decline of approximately 24.1%[13]. - The ending cash and cash equivalents balance was $101,180,684.61, a decrease from $134,911,677.55, representing a decline of about 25.1%[20]. - The total cash and cash equivalents decreased by $33,730,992.94, compared to a decrease of $90,166,947.58 in the previous period[20].

Dividend Distribution - The company plans to distribute a cash dividend of RMB 2.50 per 10 shares to all shareholders, based on a total share capital of 223,093,872 shares after excluding repurchased shares[5]. - The total number of shares for the dividend distribution is based on 223,093,872 shares after excluding 7,306,128 repurchased shares[131]. - The cash dividend represents 100% of the total distributable profit of 80,003,240.17 yuan[130]. - No stock dividends or capital reserve transfers to increase share capital are planned for 2024, with remaining undistributed profits retained for future distribution[131]. - The cash dividend distribution complies with the company's articles of association and shareholder resolutions[130]. - The company has ensured that minority shareholders have the opportunity to express their opinions and that their legal rights are protected[130]. Financial Performance - The company's operating revenue for 2024 reached ¥366,961,875.76, representing a 107.19% increase compared to ¥177,116,768.29 in 2023[19]. - Net profit attributable to shareholders for 2024 was ¥62,497,180.07, a significant increase of 220.99% from ¥19,469,949.42 in 2023[19]. - The basic earnings per share for 2024 was ¥0.28, up 250.00% from ¥0.08 in 2023[19]. - The company's cash flow from operating activities for 2024 was ¥70,963,572.50, reflecting a 332.36% increase compared to ¥16,412,959.81 in 2023[19]. - The total assets at the end of 2024 were ¥531,628,129.09, a 10.94% increase from ¥479,211,078.40 at the end of 2023[19]. - The company achieved a total revenue of 366.96 million yuan in 2024, representing a growth of 107.19% compared to the previous year[43]. - The net profit attributable to shareholders reached 62.50 million yuan, an increase of 220.99% year-on-year[43]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was 59.15 million yuan, up 297.68% from the previous year[43]. Business Expansion and Innovation - The company has expanded its business scope to include the manufacturing and sales of new film materials and paper products, reflecting a strategic diversification[17]. - The company has been actively involved in the research and development of medical devices and hygiene products, indicating a focus on innovation[17]. - The company has established partnerships with several major tobacco companies, including Yunnan Tobacco and Zhejiang Tobacco, enhancing its market position[30]. - The company focuses on high-quality, high-stability, and high-precision cigarette label production, adapting to customer needs and technological advancements[31]. - The company has added 5 invention patents and 3 utility model patents during the reporting period, with a total of 110 active national patents and 28 registered trademarks by the end of the reporting period[45]. - The company has established a doctoral workstation, marking a significant step in its research and innovation efforts[45]. - The company emphasizes innovation in product and technology systems, investing in new materials and processes to improve overall competitiveness[45]. Operational Efficiency and Cost Management - The company is actively pursuing digital transformation to enhance operational efficiency, integrating key management systems to streamline processes[46]. - The company completed the development of a high-efficiency printing ink recovery and reuse system, expected to significantly reduce production costs and environmental impact[61]. - An intelligent printing color management system was developed, enhancing color accuracy and reducing production costs, thereby improving customer satisfaction[61]. - The automatic cleaning and maintenance system for printing machines was completed, improving operational stability and reducing labor costs[61]. - The company plans to minimize the impact of raw material price changes on gross margin through scale production, centralized procurement, and cost management[90]. Governance and Compliance - The company has maintained its commitment to transparency and accuracy in financial reporting, with all board members present for the report's approval[5]. - The company has established a sound internal control system and improved governance levels in compliance with relevant laws and regulations[94]. - The company held three shareholder meetings during the reporting period, ensuring equal treatment of all shareholders and facilitating participation through online voting[95]. - The board of directors held six meetings, with all procedures compliant with regulations and complete meeting records maintained[97]. - The company maintains independence from its controlling shareholder in business, personnel, assets, and finance, ensuring autonomous operational capabilities[103]. - The company has disclosed its valuation enhancement plan and implemented a "Quality Return Dual Improvement" action plan[92]. Environmental Responsibility - The company was listed as a key pollutant discharge unit in the 2024 environmental supervision list by the Chaozhou Ecological Environment Bureau[141]. - The company strictly adhered to the emission standards for volatile organic compounds (VOCs) and wastewater, with no exceedances reported during the reporting period[142]. - The wastewater treatment process involves three-stage isolation followed by biological degradation, ensuring compliance with national discharge standards[146]. - The company has established a solid waste management protocol, including agreements with qualified disposal agencies for hazardous waste[152]. - The company has invested a total of ¥1,736,712.47 in environmental governance and protection for the year, focusing on the maintenance of environmental governance equipment, consumable replacements, and upgrades of exhaust treatment facilities[188]. Employee Management and Development - The total number of employees at the end of the reporting period was 284, with 269 from the parent company and 15 from major subsidiaries[125]. - The company adheres to a performance-based compensation system, ensuring internal equity and compliance with national labor laws[126]. - Employee training programs are in place, focusing on skill enhancement through various methods, including external trainers and internal lectures[127]. - The company emphasizes employee welfare, providing training, career development opportunities, and ensuring compliance with labor laws[194]. Market Strategy and Future Outlook - The company plans to focus on the tobacco packaging business while exploring opportunities in the new tobacco industry chain, aligning with national policies[80]. - By 2025, the company aims to upgrade production capacity and introduce intelligent manufacturing equipment to meet market demand and enhance efficiency[83]. - The company intends to accelerate industry chain integration through strategic mergers and acquisitions to optimize its business structure and ensure balanced development[85]. - The company provided an optimistic outlook for Q4 2023, projecting revenue growth of 10% to 12%[112]. - New product launches are expected to contribute an additional 200 million in revenue in the next quarter[112].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002836 证券简称：新宏泽 公告编号：2025-008 广东新宏泽包装股份有限公司股票交易异常波动公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 一、股票交易异常波动的情况介绍 广东新宏泽包装股份有限公司（证券简称：新宏泽；证券代码：002836，以下简称"公司"或"本公司"） 股票于2025年4月17日、2025年4月18日连续2个交易日收盘价格涨幅偏离值累计达到20%，根据《深圳 证券交易所交易规则》的相关规定，属于股票交易异常波动的情况。 3、公司经营情况及内外部经营环境未发生重大变化。 4、经公司自查和问询控股股东和实际控制人，公司、控股股东和实际控制人不存在关于公司的应披露 而未披露的重大事项，或处于筹划阶段的重大事项；公司控股股东和实际控制人在股票交易异常波动期 间不存在买卖公司股票的情形。 二、公司关注并核实的相关情况说明 针对公司股票交易异常波动，公司对有关事项进行了核查，并对控股股东及实际控制人就相关事项进行 了核实，现就有关情况说明如下： 1、公司前期所披露的信息不存在需 ...

证券代码：002836 证券简称：新宏泽 公告编号：2025-008 广东新宏泽包装股份有限公司 股票交易异常波动公告 广东新宏泽包装股份有限公司（证券简称：新宏泽；证券代码：002836， 以下简称"公司"或"本公司"）股票于 2025 年 4 月 17 日、2025 年 4 月 18 日连续 2 个交易日收盘价格涨幅偏离值累计达到 20%，根据《深圳证券交易所 交易规则》的相关规定，属于股票交易异常波动的情况。 二、公司关注并核实的相关情况说明 针对公司股票交易异常波动，公司对有关事项进行了核查，并对控股股东 及实际控制人就相关事项进行了核实，现就有关情况说明如下： 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 1、公司前期所披露的信息不存在需要更正、补充之处。 2、公司未发现近期公共传媒报道了可能或已经对公司股票交易价格产生较 大影响的未公开重大信息。 3、公司经营情况及内外部经营环境未发生重大变化。 4、经公司自查和问询控股股东和实际控制人，公司、控股股东和实际控制 人不存在关于公司的应披露而未披露的重大事项，或处于筹 ...

4月18日，市场收盘共67股涨停，32股封板未遂，整体封板率为67.68%。 涨停战场： 近60万手买单抢筹新宏泽（维权） 据证券时报·数据宝统计，从收盘涨停板封单量来看，新宏泽封单量最高，达59.83万手；其次是我爱我家、保税科技，涨停板封单 量分别为37.05万手、29.15万手。 以封单金额计算，14股封单金额超亿元，新宏泽、立方制药、海能达等涨停板封单资金最多，分别有5.8亿元、2.84亿元、2.03亿 元。 连续涨停天数来看，国光连锁5连板，立方制药、红宝丽、亚联机械等4连板，特力Ａ、天保基建3连板，国芳集团11日10板、ST柯 利达7日6板、*ST龙宇（维权）5日4板。 | | | | | | | 4月18日封甲资金居前的涨停股 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 代码 | 简称 | 收盘价 | 换手率 | 涨停板封单 | 封审资等 | 连权大 | 涨停原因 | | | | (元) | (%) | (万手) | (1/70) | 散 | | | 002836 | 新宏泽 | 9.69 | 1.11 | 59.83 | 5. ...

Market Overview - The Shanghai Composite Index closed at 3280.34 points, up 0.13%, while the Shenzhen Component Index closed at 9759.05 points, down 0.16% [2] - The ChiNext Index rose by 0.09%, and the Sci-Tech 50 Index increased by 0.23% [2] - Among the tradable A-shares, 3126 stocks rose, accounting for 57.95%, while 2039 stocks fell, and 229 stocks remained flat [2] Stock Performance - A total of 100 stocks hit the daily limit up, while 12 stocks hit the limit down [2] - The leading sectors for limit-up stocks included basic chemicals, light industry manufacturing, and retail, with 14, 8, and 8 stocks respectively [2] - Notably, 14 of the limit-up stocks were ST (special treatment) stocks, including *ST Gongzhi and *ST Hengli [2] Trading Activity - Stocks with the highest limit-up trading volume included Nanji E-commerce with 3168.77 million shares, followed by Xinhongze and Hongbaoli with 3131.60 million and 2045.72 million shares respectively [2] - In terms of trading volume, the stocks with the highest limit-up funds were Tuo Wei Information, Xinhongze, and Lifang Pharmaceutical, with amounts of 4.25 billion, 2.76 billion, and 2.41 billion respectively [2] Detailed Stock List - Tuo Wei Information (002261) closed at 28.38 yuan with a turnover rate of 12.41% and a limit-up volume of 1496.80 million shares [3] - Xinhongze (002836) closed at 8.81 yuan with a turnover rate of 3.03% and a limit-up volume of 3131.60 million shares [3] - Lifang Pharmaceutical (003020) closed at 25.31 yuan with a turnover rate of 1.01% and a limit-up volume of 953.20 million shares [3] - Other notable stocks include Hongbaoli (002165), Nanji E-commerce (002127), and Blue Science and Technology (601798) with significant trading volumes and funds [3][4]